2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Polycystic Ovary Syndrome
10
Insulin Resistance
7
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5
Prostatic Neoplasms
4
Diabetes Mellitus, Type 2
4
Pancreatic Neoplasms
3
Diabetes Mellitus
3
Carcinoma, Non-Small-Cell Lung
3
Urinary Bladder Neoplasms
2
Metabolic Syndrome
2
Leukoplakia, Oral
2
Leukemia, Myeloid, Chronic-Phase
2
Inflammation
2
Carotid Intimal Medial Thickness 1
2
Breast Neoplasms
2
Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene
1
Sleep Apnea, Obstructive
1
Skin Neoplasms
1
Recurrence
1
Prostatic Neoplasms, Castration-Resistant
1
Pharmacokinetics of MDV3100
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Meningioma
1
Memory Disorders
1
Lung Neoplasms
1
Liposarcoma, Myxoid
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Interventions
Cyclophosphamide
153
Dexamethasone
141
Rituximab
85
fludarabine
79
Lenalidomide
72
Cytarabine
70
Bortezomib
64
fludarabine phosphate
63
Gemcitabine
62
venetoclax
54
Etoposide
53
pomalidomide
52
pembrolizumab
52
Paclitaxel
48
Cisplatin
48
Carboplatin
48
Peripheral Blood Stem Cell Transplantation
47
Filgrastim
40
Radiotherapy
39
Busulfan
37
Calcium Dobesilate
36
Methotrexate
34
Melphalan
34
Bevacizumab
33
carfilzomib
32
Cyclosporine
32
Azacitidine
32
Mycophenolic Acid
30
Vincristine
29
Bendamustine Hydrochloride
29
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
Pioglitazone
×
Clear all
NCT01010243
2012-05-30
MM03
University of Regensburg
Phase 1/2
Unknown
54 enrolled